Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

SA Transcripts 162.15K Followers Follow Vertex Pharmaceuticals Incorporated ( VRTX ) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDT Company Participants Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Wells Fargo Securities, LLC, Research Division Awesome. Last session of the day. Thank you very much for all for joining us today. My name is Mohit Bansal. I'm one of the biotech and pharma analyst here at Wells Fargo. And I have the Vertex IR team with us, Susie Lisa, Head of IR; and Manisha Pai. She's part of the IR team as well. So thank you very much, both of you to join us. Unknown Executive Thanks for having us, Mohit. Question-and-Answer Session Mohit Bansal Wells Fargo Securities, LLC, Research Division I don't have ED, Investor Relations, sorry, I do not have the title -- thank you. So exciting times at Vertex. There's a lot more to talk about, not just CF at this point. So talk a little bit about what you are -- where investors are asking most of the questions and where you're spending most time in terms of talking about the Vertex story at this point? Unknown Executive Sure. So I think it is an exciting time, and we have sort of a catalyst-rich period coming up. So I'd say most of the conversations relate around that. I will say recent news last month, we have been getting a lot of CF questions heading into competitor data that I think ended up being not as much of a concern as many have thought. And so CF questions have gone back more towards commercial aspects, the ALYFTREK, which continues to go very well and then our Next-Gen 3.0 family of therapies that are in the pipeline. But the majority of questions, I think, focus on upcoming catalysts, and that's primarily within our new